Immutep granted US patent for cancer drug

Company News

by Rachael Jones

Biotechnology company Immutep (ASX:IMM) has received the grant of a new patent from the United States Patent Office for eftilagimod alpha in cancer.

This new patent provides intellectual property protection for Immutep’s method of treating cancer by the administration of a chemotherapy agent.

The granted patent claims support the application of efti in Immutep’s ongoing clinical trial in metastatic breast cancer.
The patent will expire on 3 October 2028.

Shares in Immutep (ASX:IMM) closed 6.25 per cent higher to 3.4 cents yesterday.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.